Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market 2019 by Company, Regions, Type and Application, Forecast to 2024

  • receipt Report ID : 184615
  • calendar_today Published On: Jul, 2019
  • file_copy Pages: 136
  • list Pharmaceuticals and Healthcare

Scope of the Report:

The global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Non-Peptide Drugs of Angiotensin II Receptor Antagonist.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Non-Peptide Drugs of Angiotensin II Receptor Antagonist market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Non-Peptide Drugs of Angiotensin II Receptor Antagonist market by product type and applications/end industries.

Market Segment by Companies, this report covers

Pfizer

Novartis

Merck

AstraZeneca

Jhonson and Johnson

Eli Lilly

Sanofi

Bristol-Myers Squibb

Bayer

GSK

Teva Pharmaceutical

Shenzhen Salubris Pharmaceuticals 

Sun Pharmaceutical

Mylan

Alembic Pharmaceuticals

Lupin

Aurobindo Pharma

Amneal Pharmaceuticals

Boehringer Ingelheim

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Valsartan

Irbesartan

Candesartan Cilexetil

Eprosartan

Irbesartan

Telmisartan

losartan

Olmesartan Medoxomil

Allisartan isoproxil

Market Segment by Applications, can be divided into

High Blood Pressure

Congestive Heart Failure

Left Ventricular Hypertrophy

Atherosclerosis

Other

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Overview

1.1 Product Overview and Scope of Non-Peptide Drugs of Angiotensin II Receptor Antagonist

1.2 Classification of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Types

1.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Comparison by Types (2019-2024)

1.2.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Types in 2018

1.2.3 Valsartan

1.2.4 Irbesartan

1.2.5 Candesartan Cilexetil

1.2.6 Eprosartan

1.2.7 Irbesartan

1.2.8 Telmisartan

1.2.9 losartan

1.2.10 Olmesartan Medoxomil

1.2.11 Allisartan isoproxil

1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market by Application

1.3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Market Share Comparison by Applications (2014-2024)

1.3.2 High Blood Pressure

1.3.3 Congestive Heart Failure

1.3.4 Left Ventricular Hypertrophy

1.3.5 Atherosclerosis

1.3.6 Other

1.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market by Regions

1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (Million USD) Comparison by Regions (2014-2024)

1.4.1 North America (USA, Canada and Mexico) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)

1.4.4 South America (Brazil, Argentina, Colombia) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Status and Prospect (2014-2024)

1.5 Global Market Size of Non-Peptide Drugs of Angiotensin II Receptor Antagonist (2014-2024)

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.2 Novartis

2.2.1 Business Overview

2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.3 Merck

2.3.1 Business Overview

2.3.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.4 AstraZeneca

2.4.1 Business Overview

2.4.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.5 Jhonson and Johnson

2.5.1 Business Overview

2.5.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.6 Eli Lilly

2.6.1 Business Overview

2.6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.7 Sanofi

2.7.1 Business Overview

2.7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.8 Bristol-Myers Squibb

2.8.1 Business Overview

2.8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.9 Bayer

2.9.1 Business Overview

2.9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.10 GSK

2.10.1 Business Overview

2.10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.11 Teva Pharmaceutical

2.11.1 Business Overview

2.11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.12 Shenzhen Salubris Pharmaceuticals 

2.12.1 Business Overview

2.12.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.13 Sun Pharmaceutical

2.13.1 Business Overview

2.13.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.14 Mylan

2.14.1 Business Overview

2.14.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.14.2.1 Product A

2.14.2.2 Product B

2.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.15 Alembic Pharmaceuticals

2.15.1 Business Overview

2.15.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.15.2.1 Product A

2.15.2.2 Product B

2.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.16 Lupin

2.16.1 Business Overview

2.16.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.16.2.1 Product A

2.16.2.2 Product B

2.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.17 Aurobindo Pharma

2.17.1 Business Overview

2.17.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.17.2.1 Product A

2.17.2.2 Product B

2.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.18 Amneal Pharmaceuticals

2.18.1 Business Overview

2.18.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.18.2.1 Product A

2.18.2.2 Product B

2.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

2.19 Boehringer Ingelheim

2.19.1 Business Overview

2.19.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Type and Applications

2.19.2.1 Product A

2.19.2.2 Product B

2.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2017-2018)

3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Competition, by Players

3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Share by Players (2014-2019)

3.2 Market Concentration Rate

3.2.1 Top 5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share

3.2.2 Top 10 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share

3.3 Market Competition Trend

4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions

4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Market Share by Regions

4.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

4.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

4.4 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

4.5 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

4.6 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

5 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries

5.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)

5.2 USA Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

5.3 Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

5.4 Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

6 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries

6.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)

6.2 Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

6.3 UK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

6.4 France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

6.5 Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

6.6 Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries

7.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)

7.2 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

7.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

7.4 Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

7.5 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

7.6 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

8 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries

8.1 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)

8.2 Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

8.3 Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

8.4 Colombia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Countries

9.1 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Countries (2014-2019)

9.2 Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

9.3 UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

9.4 Egypt Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

9.5 Nigeria Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

9.6 South Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2014-2019)

10 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segment by Type

10.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Market Share by Type (2014-2019)

10.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Type (2019-2024)

10.3 Valsartan Revenue Growth Rate (2014-2024)

10.4 Irbesartan Revenue Growth Rate (2014-2024)

10.5 Candesartan Cilexetil Revenue Growth Rate (2014-2024)

10.6 Eprosartan Revenue Growth Rate (2014-2024)

10.7 Irbesartan Revenue Growth Rate (2014-2024)

10.8 Telmisartan Revenue Growth Rate (2014-2024)

10.9 losartan Revenue Growth Rate (2014-2024)

10.10 Olmesartan Medoxomil Revenue Growth Rate (2014-2024)

10.11 Allisartan isoproxil Revenue Growth Rate (2014-2024)

11 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segment by Application

11.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application (2014-2019)

11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Application (2019-2024)

11.3 High Blood Pressure Revenue Growth (2014-2019)

11.4 Congestive Heart Failure Revenue Growth (2014-2019)

11.5 Left Ventricular Hypertrophy Revenue Growth (2014-2019)

11.6 Atherosclerosis Revenue Growth (2014-2019)

11.7 Other Revenue Growth (2014-2019)

12 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast (2019-2024)

12.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast (2019-2024)

12.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Regions (2019-2024)

12.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)

12.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)

12.5 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)

12.6 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)

12.7 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Non-Peptide Drugs of Angiotensin II Receptor Antagonist Picture

Table Product Specifications of Non-Peptide Drugs of Angiotensin II Receptor Antagonist

Table Global

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery